ArticleFrontiers in cell and developmental biology2026
Resveratrol reverses doxorubicin-resistance and alleviates doxorubicin-induced myocardial injury in hepatocellular carcinoma.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Doxorubicin (DOX) chemotherapy for hepatocellular carcinoma is hampered by tumor multidrug resistance and cumulative cardiotoxicity. Resveratrol (RES), a natural polyphenol with anti-tumor and antioxidant effects, may reverse DOX resistance and mitigate myocardial injury. Objective: To investigate whether RES reverses DOX resistance and boosts anti-tumor activity in HepG2-R/SMMC-7721-R cells via apoptosis and EMT regulation, while protecting H9c2 cardiomyocytes; an H22 tumor-bearing mouse model was used to confirm the dual Methods: Results: DOX monotherapy barely inhibited resistant cell growth, while RES alone exerted weak anti-tumor activity; RES + DOX exerted obvious combined cytotoxicity to suppress proliferation, metastasis and induce tumor apoptosis. RES reversed EMT and enhanced the activation of Bax/Bcl-2/caspase-3 signaling. In H9c2 cells, RES eliminated DOX-triggered ROS overload, restored SOD, lowered MDA and suppressed cardiomyocyte apoptosis. Conclusion: RES reverses DOX resistance and enhances anti-tumor effects; this finding is associated with the regulation of apoptosis and EMT signaling, and alleviates DOX-mediated cardiomyocyte oxidative injury through antioxidant pathways. This dual-action adjuvant strategy widens DOX´s therapeutic window for DOX-resistant hepatocellular carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.